AI-PROGNOSIS is making significant strides towards the launch of the Digital Biomarkers Development, Validation, and Verification Study (dBM-DEV study).

Our current focus is on testing the successful collection of data from our smartwatch, which includes metrics such as accelerometer data, BBI, and heart rate.

Testing is actively underway with our partners, including SquareDev, Aristotle University of Thessaloniki (AUTH), and clinical sites CHU de Toulouse, Fundación INCE, King’s College London, and Technische Universität Dresden. In the coming weeks, we will also see technical partners Netcompany-Intrasoft, Centre for Research & Technology Hellas (CERTH), and KU Leuven begin their testing phases.

As we progress, we will incorporate additional features, such as cognitive and motor tests, and continue to enhance the app’s overall functionality.

Upon successful completion of the testing phase, the dBM-DEV study will commence. We look forward to sharing further updates as we advance towards this important milestone.